If minimizing the depth and duration of sedation is accepted as a desirable goal, then the use of a short-acting agent with an effect that can be rapidly adjusted such as propofol or remifentanil should offer advantages over longer-acting agents or agents with active metabolites. As compared with benzodiazepines, propofol has not been shown to reduce mortality but may result in a reduction in the length of stay in the ICU.